MYoroface named one of the fastest growing companies in Europe

MYoroface, the Swedish healthtech company behind the IQoro, has been named one of the fastest growing companies in Europe. The award comes from the annual FT 1000 report developed by The Financial Times, which ranks European companies that have achieved the highest growth in recent years.

In the UK, around 13 million people suffer from reflux. In 2022, IQoro gained NHS prescription status and today it is prescribed to patients throughout the country. See image for distribution.

The only Swedish company to qualify in the category health care & life sciences

MYoroface is the only Swedish company to qualify for the list in the Health Care & Life Sciences category. The company was founded in 2012 in Hudiksvall and has since grown to have customers throughout Europe.

Procured by the worlds largest health organisation

IQoro, the company’s main product, is a medical device (class I), CE marked and recognized by NICE (National Institute for Health and Care Excellence). Last year, the company also grew from 15 to 23 employees and was procured by the world’s largest health organization, the National Health Service.

Over 80,000 customers have been helped

IQoro treats the root cause of reflux, snoring and eating and swallowing difficulties. With a simple 90-second treatment session per day, IQoro treats the root cause of these symptoms and provides an improved quality of life. The device is based on over 20 years of scientific clinical research and has helped over 80,000 people regain their ability to eat, drink and sleep normally.

Demonstration of a successful growth strategy

Johan Hedqvist, CFO at MYoroface, says: “We are very proud to be the only Swedish company on the FT 1000 list in Health Care & Life Sciences category. This demonstrates MYoroface’s successful growth strategy and our strong commitment to helping people live healthier and more productive lives. We are convinced that IQoro will continue to revolutionize the treatment of reflux, snoring and swallowing difficulties.”

One of the leading players in the industry

The FT 1000 list ranks the fastest growing European companies based on their annual growth. MYoroface is one of the selected companies on the list in the Health Care & Life Sciences category and the company’s performance confirms its position as one of the leading players in the industry.

For more information, please contact:

Linn Hägg

004670-344 89 55

linn.hagg@myoroface.com